Remarks

Claims 1 to 28 are pending in the application and all were rejected under 35 U.S.C. §102(b) in view of Kabara (EP0530861A2). Claims 1, 3 to 5, 7 to 10, 12, and 16 to 25 were rejected under 35 U.S.C. §112, first paragraph, because the examiner contends that sorbitol (which is recited in these claims) is not specifically named in the specification. The examiner also contends that: one would not arrive at a minimum dielectric constant of 25 from the data in the specification; and all fatty acids must be even numbered hydrocarbons 6-18 because all fatty acids are synthesized 2 c atoms at a time (citing Morrison, p. 1132, 1134).

On February 18, 2005, Applicants submitted a Terminal Disclaimer traversing an earlier rejection based on obviousness-type double patenting. Receipt of the terminal disclaimer has been acknowledged by the examiner. (Action, p.2.) It is assumed that the double-patenting rejection has been withdrawn.

The examiner's contentions that one would not include sorbitol or arrive at a minimum dielectric constant of 25 from the data in the application are incorrect. At page 23, lines 14 to 21 the specification discloses polarity or conductivity of a material being measured in terms of the dielectric constant, as well as the extremes of suitable dielectric constants. Materials at the low end have unacceptable dielectric "constants in the range of 15 to 25." Claim 11 recites a dielectric constant "greater than 25." Therefore, there is a disclosure and a teaching of a lower limit of a lipophilic polar solvent having a dielectric constant of greater than 25. Since sorbitol has a dielectric constant of 33.5, it is well within the teachings of the present application. Applicants respectfully submit that the rejection under 35 U.S.C. §112 should be withdrawn, and that this claim should be allowed. Sorbitol specifically, and dielectric constants above 25 Applicant: Dee et al.

Application No.: 10/786,209

generally, are supported by the above-cited portion of the specification and there is no such

teaching of the claimed range in the prior art.

As to the examiner's contention that claim 17 is not allowable because C7 cannot be a

fatty acid, Applicants respectfully disagree. In the specification at page 5, lines 4 to 10,

Applicants describe "a mixture of fatty acids (C6 to C12) to solublize the fatty acids. In such a

composition, the shorter-chained fatty acids (C₆ to C₉) may actually assist the action of the

hydrotrope by helping to solublize the longer species, and thereby improving the longer species'

antimicrobial efficacy." In this passage, it is evident that Applicants were teaching that a C₉ fatty

acid was indeed a "fatty acid" by the inventors' definition.

While Morrison (cited by the examiner) discusses the synthesis of fatty acids as taking

place "two carbons at a time," there is nothing in Morrison that excludes a compound because it

has an odd number of carbon atoms. Regardless, Morrison's definition is not controlling.

Inventors are permitted to be their own lexicographers. Lear Siegler, Inc. v. Aeroquip Corp., 773

F.2d 881, 889, 221 U.S.P.Q. 1025, 1031 (Fed. Cir. 1984). Here, the inventors were using the

term fatty acids to include C9, which obviously has an odd number of carbon atoms. Thus, C7

fatty acids are supported by the specification and are allowable under 35 U.S.C. §112 and over

the art of record.

In their June 22, 2005 response, Applicants noted that Kabara (EP0530861A2) cannot

anticipate or render obvious the claims of this application because it requires the presence of a

fatty acid ester. The claims of this application expressly exclude compositions comprising fatty

acid esters. The examiner seems to be taking the position that the "devoid of" language in the

rejected claims is improper or ineffective, per se.

3

Applicant: Dee et al.

Application No.: 10/786,209

There is no per se rule against such negative limitations. In re Bankowski, 318 F.2d 778,

782-83, 138 U.S.P.Q. 75, 79 (CCPA 1963). The examiner has not cited any prior art equivalents

or descriptions of fatty acid esters that would render the claims indefinite for possibly including

the prior art teachings. Thus, nothing in the record supports the examiner's contention that the

claims at issue are indefinite or anticipated by Kabara.

In In re Duva, 387 F.2d 402, 408, 156 U.S.P.Q. 90, 95 (CCPA 1967), the court held that

the phrase "absent sufficient CN ions to prevent disposition induced by said palladous salt," was

not indefinite since the claims "affirmatively specify the constitution" of the claimed subject

matter. Similarly here, Applicants have affirmatively specified that the claimed composition is

"devoid of sufficient fatty acid ester to substantially improve the antimicrobial activity of the

composition." Applicants have limited their claims to exclude fatty acid esters because Kabara

teaches the need for fatty acid esters. No further limitation is necessary under §112 or to avoid

the prior art.

Conclusion

For the foregoing reasons, Applicants respectfully submit that this application is

allowable and should be passed to issue.

Respectfully submitted,

Jeffry W. Smith, Reg. No. 33455

Attorney for Applicant SMITH LAW OFFICE

440 Science Drive, Suite 302

Madison, WI 53711

(608) 663-8200

4